Related Experiment Videos
Chemotherapy of human tumor xenografts in genetically athymic mice
Abstract:
A series of studies were undertaken to evaluate the chemotherapeutic response to various antineoplastic drugs of human breast (MX-1) or colon (CX-2) tumor xenografts growing in genetically athymic (nude) mice. Fragments (2mm3) of either tumor type were implanted subcutaneously into the subaxillary region of NIH Swiss nude mice, and single drug therapy was started when tumors became palpable and were growing progressively. 5-Fluorouracil (5-FU) administered on a Q7DX3 schedule starting on Day 21 post tumor implantation elicited significant retardation in the growth rate of CX-2 tumor. A single treatment with methyl-CCNU induced temporary tumor regression. Against MX-1 tumor, both cyclophosphamide and melphalan induced tumor regressions with no recurrence. 5-FU slowed but did not arrest growth of MX-1 tumor. These tumor systems grown in nude mice appear to be suitable models for in vivo screening of anticancer agents that would prove clinically active.
Insights
This study evaluated anticancer drugs in human breast and colon tumor models grown in nude mice. Certain drugs showed significant tumor growth inhibition or regression, suggesting these models are effective for screening new cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Evaluating the efficacy of chemotherapeutic agents is crucial for cancer treatment development.
- Genetically athymic (nude) mice xenografts provide a platform for in vivo drug screening.
- Human breast (MX-1) and colon (CX-2) tumor models were utilized to assess drug responses.
Purpose of the Study:
- To assess the chemotherapeutic response of human breast (MX-1) and colon (CX-2) tumor xenografts.
- To evaluate the efficacy of specific antineoplastic drugs in vivo.
- To determine the suitability of these xenograft models for preclinical anticancer agent screening.
Main Methods:
- Human breast (MX-1) and colon (CX-2) tumor fragments were implanted into NIH Swiss nude mice.
- Single-agent chemotherapy was initiated upon palpable tumor growth.
- Drugs evaluated included 5-Fluorouracil (5-FU), methyl-CCNU, cyclophosphamide, and melphalan.
Main Results:
- 5-Fluorouracil (5-FU) significantly retarded CX-2 tumor growth.
- Methyl-CCNU induced temporary regression in one tumor type.
- Cyclophosphamide and melphalan achieved complete regression of MX-1 tumors without recurrence; 5-FU only slowed MX-1 tumor growth.
Conclusions:
- The MX-1 and CX-2 tumor xenograft models in nude mice are effective for evaluating anticancer drug activity.
- Specific chemotherapeutic agents demonstrated varying degrees of efficacy against these human tumor models.
- These models show promise for the in vivo screening of potentially clinically active anticancer agents.